Cargando…
Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines
BACKGROUND: Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein si...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087127/ https://www.ncbi.nlm.nih.gov/pubmed/24970389 http://dx.doi.org/10.1186/1752-0509-8-75 |